Translational Development Acquisition Corp.
NASDAQ:TDACShell Companies
-$0.01 today
- Market cap
- $267.99M
- Beta
- 0.01
- P/E (TTM)
- 29.8
- EPS (TTM)
- $0.36
Volume 0.47M
Average 0.10M
TDAC Interest Income
Income earned on cash, deposits, and investments held by the company.
Translational Development Acquisition Corp.NASDAQ: TDAC
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income remains negative
Q1 FY2026 interest income was $0, compared with $0 a year earlier. Trailing-twelve-month interest income was $1.87M.
Context
- Interest income increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $468.45K.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Interest Income vs competitors
How TDAC compares with its peers on the latest reported figures
- TDAC's LTM Mar 2026 interest income of $1.87M is the 6th highest of the 7 companies compared; the peer median is $5.65M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.05M | — | +42.6% | — | |
| LTM Mar 2026 | $8.19M | +590.4% | — | — | |
| LTM Mar 2026 | $6.98M | +177.3% | +14.4% | — | |
| FY2022 | $4.31M | — | — | — | |
MACIMelar Acquisition Corp. I | LTM Mar 2026 | $2.23M | -49.5% | — | — |
| LTM Mar 2026 | $1.87M | — | — | — | |
NTWONewbury Street II Acquisition Corp | LTM Mar 2026 | -$234.97K | -107.7% | — | — |
| Peer median (excluding TDAC) | $5.65M | +63.9% | +28.5% | — | |
Competitors are the stored peer set for TDAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 1.07M | 0 |
| Cost of Revenue | 0 | 0 | 320.87K | 0 |
| Gross Profit | 0 | 0 | 744.92K | 0 |
| Gross Margin | — | — | 69.9% | — |
| Research & Development | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 70.66K | 485.55K | 196.36K | 944.54K |
| Operating Expenses | 70.66K | 485.55K | 196.36K | 944.54K |
| Depreciation & Amortization | 70.66K | 0 | 0 | 0 |
| EBITDA | 0 | (485.55K) | (71.01K) | (944.54K) |
| EBITDA Margin | — | — | -6.7% | — |
| Operating Income | (70.66K) | (485.55K) | (196.36K) | (944.54K) |
| Operating Margin | — | — | -18.4% | — |
| Interest Income | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 508.56K | 0 |
| Other Income / Expenses | 0 | 0 | 125.35K | 7.31M |
| Income Before Tax | (70.66K) | (485.55K) | (71.01K) | 6.36M |
| Pre-Tax Margin | — | — | -6.7% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (70.66K) | (485.55K) | (71.01K) | 6.36M |
| Net Margin | — | — | -6.7% | — |
| EPS (Basic) | (0.02) | (0.12) | (0.02) | 0.37 |
| EPS (Diluted) | (0.02) | (0.12) | (0.02) | 0.37 |
| Weighted Avg Shares | 4.05M | 4.05M | 4.05M | 17.25M |
| Weighted Avg Shares (Diluted) | 4.05M | 4.05M | 4.05M | 17.25M |
Translational Development Acquisition Corp.
NASDAQ:TDAC
Intrinsic Alpha fair value
Locked
Current Price
$10.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.